Latest filing published 09 Jun 2020 for Evofem Biosciences, Inc., €25.9M.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Acacia Research Corp: trading record in brief
Acacia Research Corp has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Veritone, Inc., Drive Shack Inc. and Evofem Biosciences, Inc. Over a trading history stretching from 17 May 2017 to 4 June 2020, the count stands at 19 filings.
The open-market side counts 4 purchases for €2.1M alongside 9 sales for €47.3M. Netting one side against the other leaves €45.2M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants. Since January 2020: no purchases and 1 sale on the market.
Half of the purchases are above €374k and half below. The 4 purchases reviewed show no overlap with other insiders buying the same stock within a month.
The latest filing, published on 9 June 2020, reports an open-market sale of €25.9M in Evofem Biosciences, Inc. The last insider purchase was made public on 26 December 2019, 2,510 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Acacia Research Corp
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 9,138,504 shares@ US$3.21Common Stock, par value $0.0001 per shareSEC:0000902664-20-002335:0
- 74,100 shares@ US$3.7311.7% of flowCommon Stock, par value $0.01 per share ("Common Stock")SEC:0000902664-19-004675:0Canonical exit: 16 Mar 2020 (T+90)
- 91,600 shares@ US$4.1016.0% of flowCommon Stock, par value $0.01 per share ("Common Stock")SEC:0000902664-19-004380:0Canonical exit: 12 Feb 2020 (T+90)
- 108,400 shares@ US$4.1319.1% of flowCommon StockSEC:0000902664-19-004380:1Canonical exit: 13 Feb 2020 (T+90)
- 300,000 shares@ US$4.1853.3% of flowCommon StockSEC:0000902664-19-004380:2Canonical exit: 16 Feb 2020 (T+90)
- 250,000 shares@ US$5.215.9% of flowVERI Common StockSEC:0000934549-19-000003:0
- 284,748 shares@ US$4.816.2% of flowVERI Common StockSEC:0000934549-19-000003:1
- 82,275 shares@ US$6.372.4% of flowCommon StockSEC:0000934549-18-000096:0
- 117,725 shares@ US$6.113.3% of flowCommon StockSEC:0000934549-18-000096:1
- 1,500,000 shares@ US$5.0134.6% of flowCommon StockSEC:0000934549-18-000094:0
- 1,000,000 shares@ US$10.5047.6% of flowCommon StockSEC:0000934549-18-000086:0
- 1,523,746 shares@ US$13.61Secured Convertible Promissory NoteSEC:0000934549-17-000025:0
- 2,150,335 shares@ US$13.61Primary Common Stock Purchase WarrantSEC:0000934549-17-000025:1
- 295,440 shares@ US$13.61Secured Convertible Bridge NoteSEC:0000934549-17-000025:2
14 of 14 declarations